Abstract
Human T cells adopt a CD28-CD57+ phenotype in chronic viral infections and this has been hypothesized to result from continuous stimulation, however this phenotype may be due to direct viral effects on T cells. Employing MS patients before and after chronic in vivo administration of the antigen glatiramer acetate (GA) we examine this hypothesis. Pre-treatment glatiramer acetate-specific CD8 T cells were CD57-Perforin-. This changed to a predominantly CD28-CD57+Perforin+ response after administration of this drug. This phenotype was only observed after chronic stimulation and not in a recall response to mumps. The relevance to GA's mechanism of action is discussed.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
CD28 Antigens / immunology*
-
CD4-Positive T-Lymphocytes / drug effects
-
CD4-Positive T-Lymphocytes / immunology
-
CD57 Antigens / immunology
-
CD8-Positive T-Lymphocytes / drug effects*
-
CD8-Positive T-Lymphocytes / immunology
-
Female
-
Flow Cytometry
-
Glatiramer Acetate
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Male
-
Membrane Glycoproteins / metabolism
-
Middle Aged
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / immunology*
-
Peptides / therapeutic use*
-
Perforin
-
Pore Forming Cytotoxic Proteins
-
T-Lymphocyte Subsets / drug effects*
-
T-Lymphocyte Subsets / immunology
Substances
-
CD28 Antigens
-
CD57 Antigens
-
Immunosuppressive Agents
-
Membrane Glycoproteins
-
Peptides
-
Pore Forming Cytotoxic Proteins
-
Perforin
-
Glatiramer Acetate